A medical device company developing technology to improve outcomes for stroke patients will begin enrollment for a new ...

Mesoblast Limited recently announced positive Phase III trial results in the European Journal of Heart Failure.

A machine learning model for analysing brain lesion scans after stroke could mean up to 50% more patients receive appropriate ...

CLEAN trial of endovascular therapy within 6 h of onset of ischaemic stroke caused by intracranial internal carotid or proximal middle cerebral artery occlusion were presented at the 9th World Stroke ...

RapidPulse, Inc. announced FDA approval of an investigational device exemption (IDE) for the company to study the RapidPulse c ...

GNT Pharma Co. Ltd, a late-stage pharmaceutical company founded in 1998 with offices in Seoul Korea, Italy and USA, announced today the ...

Inretio presents initial clinical trial results at prestigious BRAIN Conference 2024 in London.Toronto, Ontario--(Newsfile Corp. - December 11, ...

This study assesses acute ischemic stroke costs in Latin America, revealing treatment variations and economic challenges that ...

Researchers suggest an application to FDA may be made within the next 12 months, requesting approval to carry out a human clinical trial with the gene therapy.

In a single IV injection, a gene therapy targeting cBIN1 can reverse the effects of heart failure and restore heart function in a large animal model. The therapy increases the amount of blood the ...

Hepatocellular carcinoma (HCC) stands as the dominant form of liver cancer, ranking as the fourth leading cause of cancer-related deaths globally ...

Moyamoya disease (Moyamoya disease) is a disease in which the terminal part of arterial blood vessels in the brain that ...